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Amyotrophic lateral sclerosis (ALS) and spinal and bulbar muscular atrophy (SBMA) are
two motoneuron diseases (MNDs) characterized by aberrant protein behavior in affected
cells. In familial ALS (fALS) and in SBMA specific gene mutations lead to the production
of neurotoxic proteins or peptides prone to misfold, which then accumulate in form of
aggregates. Notably, some of these proteins accumulate into aggregates also in sporadic
ALS (sALS) even if not mutated. To prevent proteotoxic stresses detrimental to cells,
misfolded and/or aggregated proteins must be rapidly removed by the protein quality
control (PQC) system. The small heat shock protein B8 (HSPB8) is a chaperone induced
by harmful events, like proteasome inhibition. HSPB8 is expressed both in motoneuron
and muscle cells, which are both targets of misfolded protein toxicity in MNDs. In
ALS mice models, in presence of the mutant proteins, HSPB8 is upregulated both in
spinal cord and muscle. HSPB8 interacts with the HSP70 co-chaperone BAG3 and
enhances the degradation of misfolded proteins linked to sALS, or causative of fALS and
of SBMA. HSPB8 acts by facilitating autophagy, thereby preventing misfolded protein
accumulation in affected cells. BAG3 and BAG1 compete for HSP70-bound clients and
target them for disposal to the autophagy or proteasome, respectively. Enhancing the
selective targeting of misfolded proteins by HSPB8-BAG3-HSP70 to autophagy may
also decrease their delivery to the proteasome by the BAG1-HSP70 complex, thereby
limiting possible proteasome overwhelming. Thus, approaches aimed at potentiating
HSPB8-BAG3 may contribute to the maintenance of proteostasis and may delay MNDs
progression.
Keywords: motoneuron diseases, amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, proteasome,
autophagy, chaperones, misfolded proteins, HSPB8
INTRODUCTION
Motoneuron diseases (MNDs) are neurodegenerative diseases (NDs) in which cortical and/or
spinal motoneurons are affected. They appear in sporadic or familial forms; little is known
on alterations inducing sporadic MNDs, while specific gene mutations are responsible for
altered RNA or protein functions in familial MNDs pathogenesis. Mutations may affect
RNA/protein synthesis or activity (loss-of-function) or induce neurotoxicity (gain-of-
functions). Amyotrophic lateral sclerosis (ALS) and spinal and bulbar muscular atrophy
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 June 2017 | Volume 10 | Article 176
Rusmini et al. HSPB8 and Motoneuron Diseases
(SBMA) are MNDs mainly associated with gain-of-functions in
proteins which become resistant to folding or conformationally
unstable, leading to unfolding/misfolding. Misfolded proteins
are prone to aggregate and neurotoxic impairing several cellular
functions causing cell death. To prevent misfolded proteins
toxicity, cells activate a protein quality control (PQC) system,
which surveys protein folding and clears damaged substrates.
The PQC system is crucial to counteract the neurotoxic events
triggered by misfolded proteins and thus should be considered
as a potential target for therapeutic intervention to ameliorate
MNDs course.
THE PROTEIN QUALITY CONTROL
SYSTEM
The PQC system is composed of molecular chaperones and
degradative pathways.
Chaperones, like the heat shock proteins (HSPs), are
often constitutively expressed, but also over-induced by
different cell stresses (Morimoto, 2006), and include more
than 150 members (grouped on the basis of their size (small
HSPs, HSP40s, HSP60s, HSP70s, HSP90s and HSP100),
structure and function; Kampinga and Craig, 2010). Several
chaperones require co-chaperones, which act as nucleotide
exchange factors (NEFs), like the BCL2-associated athanogene
(BAG) family of proteins (Takayama and Reed, 2001).
Several chaperones and co-chaperones are mutated in NDs
or other diseases characterized by neuronal loss (Smith
et al., 2015), suggesting that they are protective against
neurodegeneration. Chaperones directly assist the proper
folding of nascent proteins or refold denatured existing proteins.
When folding fails, chaperones route unfolded, partially
folded or misfolded proteins to degradation. During cell stress
(i.e., presence of misfolded proteins), some HSPBs, like heat
shock protein B8 (HSPB8), limit the levels of aberrant proteins
escaping degradation, which can accumulate in cells (Crippa
et al., 2010b; Minoia et al., 2014; Cristofani et al., 2017a;
Figure 1).
The degradative pathways include the ubiquitin-proteasome
system (UPS) and the autophagy (also the unfolded protein
response (UPR), which relies on a specific endoplasmic reticulum
associated degradation (ERAD) is part of the PQC but extensively
reviewed recently (Volpi et al., 2017)). UPS and autophagy
are in a finely orchestrated equilibrium, controlled by specific
chaperones and co-chaperones (Gamerdinger et al., 2011a;
Lilienbaum, 2013;Minoia et al., 2014; Behl, 2016; Cristofani et al.,
2017a). UPS has low capacity, but high selectivity for monomeric
misfolded proteins. An example of chaperone complex targeting
misfolded proteins to UPS is formed by BAG1, HSP70 and
the E3-ubiquitin ligase CHIP/STUB1 (Figure 1). Autophagy
has high capacity, but low selectivity for substrates degrading
oligo-/hetero-meric species, aggregates and damaged organelles
(Klionsky et al., 2016). An example of chaperone complex
targeting misfolded proteins to autophagy is the chaperone-
assisted selective autophagy (CASA) complex, composed of
HSPB8, BAG3, HSP70 and CHIP/STUB1. CASA complex
interacts with the autophagy receptor SQSTM1/p62 which binds
both ubiquitinated proteins and lipidated LC3 (LC3-II) targeting
proteins to autophagosomes for degradation (Klionsky et al.,
2016; Figure 1).
An imbalance of these two degradative pathways plays
deleterious effects in several NDs (Kakkar et al., 2014;
Ciechanover and Kwon, 2015; Nikoletopoulou et al., 2015; Senft
and Ronai, 2015; Xilouri and Stefanis, 2015).
ALS AND SBMA AS MODELS TO STUDY
MISFOLDED PROTEINS IN MNDs
ALS is a MND involving brain motor cortex, brainstem and
anterior horn spinal cord motoneurons. Neurons of the fronto-
temporal brain regions could be involved (Robberecht and
Philips, 2013), causing mixed motor and cognitive phenotype
(ALS with fronto-temporal dementia or FTD). Other cells, like
glial cells (astrocytes (Trotti et al., 1999; Boillée et al., 2006; Nagai
et al., 2007), oligodendrocytes (Philips et al., 2013), Schwann cells
(Lobsiger et al., 2009; Turner et al., 2010), microglia (Philips
and Robberecht, 2011)), and muscle cells (Musarò, 2010; Onesto
et al., 2011; Galbiati et al., 2014) modulate disease progression,
affecting motoneuron functions and survival capability.
ALS are mainly sporadic (sALS), with only 15% familial
(fALS) forms, clinically indistinguishable from sALS. fALS
are linked to specific gene mutations (e.g., superoxide
dismutase-1 (SOD1), TAR DNA-binding protein 43 (TDP-43),
fused-in-sarcoma/translocated-in-liposarcoma (FUS/TLS),
Sequestosome-1 (SQSTM1/p62), Optineurin (OPTN-1),
Ubiquilin (UBQLN-2), Valosin Containing Protein (VCP),
TANK Binding Kinase 1 (TBK1) and several others (see Taylor
et al., 2016 for review). Many of these gene products are
autophagy-related proteins, key players of the PQC system
(Ju et al., 2009; Tresse et al., 2010; Seguin et al., 2014; Taylor
et al., 2016), or mislocalize and aggregate exerting proteotoxicity
(Robberecht and Philips, 2013; Taylor et al., 2016). Some of these
proteins are prone to aggregate in sALS even in their wild-type
form (e.g., TDP-43, FUS, SQSTM1/p62, OPTN-1, UBQLN-2,
etc.), suggesting that the mutation exacerbates their natural
propensity to misfold (Neumann et al., 2006; Daoud et al., 2009;
Bosco and Landers, 2010) and that common toxic mechanisms
are involved in fALS and sALS. About 50% of fALS are linked to
GGGGCC hexanucleotide (or G4C2) repeat expansions in the
C9ORF72 gene (Al-Sarraj et al., 2011; DeJesus-Hernandez et al.,
2011; Renton et al., 2011); this repeat undergoes a non-canonical
repeat-associated non-ATG (RAN) translation, which generates
five different dipeptides (DPRs), highly aggregation-prone (Ash
et al., 2013; Lashley et al., 2013; Mori et al., 2013).
SBMA differs from ALS by a slower progression rate and
involves lower motoneurons, dorsal root ganglia (DRG) sensory
neurons, muscle cells and different androgen-target cells in
reproductive tissues. Glial cells or microglia are not involved
(La Spada et al., 1991; Fischbeck, 1997; Sorarù et al., 2008;
Boyer et al., 2013; Malena et al., 2013; Cortes et al., 2014;
Lieberman et al., 2014). SBMA is linked to a CAG repeat
expansion in the androgen receptor (AR) gene, which codes
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FIGURE 1 | Proteostasis in neurodegenerative disorders. Molecular chaperones assist proteins to acquire the proper folding. When folding fails, the chaperones
allow the ubiquitination and route misfolded proteins to degradative systems. This process is mediated by the HSC70-CHIP complex that interacts with nucleotide
exchange factor (NEF)/BCL2-associated athanogenes (BAGs; HSC70 co-chaperones). BAG1 routes misfolded proteins to ubiquitin proteasome system (UPS).
Alternatively, BAG3 and specific chaperone heat shock protein B8 (HSPB8; B8 in the figure) promote the degradation of HSC70 substrates via autophagy. The
HSC70-CHIP interaction with BAG1 inhibits the HSP70 chaperone activity and allows misfolded proteins polyubiquitination by HSC70-binding co-factor CHIP
resulting in misfolded proteins degradation via UPS. BAG3 interacts with dynein and 14-3-3 protein moving misfolded proteins to microtubule organization center
(MTOC) where aggresomes are assembled. Polyubiquitinated proteins linked to HSC70-BAG3 are recognized by SQSTM1/p62 and its interaction with LC3 allows
misfolded proteins insertion into autophagosomes.
an elongated polyglutamine tract (polyQ) in the AR protein
(ARpolyQ; La Spada et al., 1991). ARpolyQ tends to misfold
acquiring neurotoxic properties (Poletti, 2004), but only after
binding to its ligand testosterone (Stenoien et al., 1999; Simeoni
et al., 2000; Katsuno et al., 2002, 2003). Testosterone triggers
conformational changes required for AR activation possibly
impaired by the polyQ.
Several studies prove that misfolded proteins accumulation
in fALS, sALS or SBMA alters the degradative pathways.
The UPS could be overwhelmed by an excess of misfolded
proteins or clogged by the polyQ (Ciechanover and Kwon, 2015;
Rusmini et al., 2016); the autophagic flux could be blocked by
misfolded protein aggregates (Rusmini et al., 2013). However,
the molecular steps altered by misfolded proteins in these
pathways are poorly understood. Several chaperones enhance
misfolded protein degradation either/both by facilitating their
proteasomal degradation or/and by limiting autophagic flux
alterations (Balchin et al., 2016; Rusmini et al., 2016; van Noort
et al., 2017; Charmpilas et al., 2017).
THE HSPB8 FUNCTIONS AND ITS ROLE IN
ALS AND SBMA
HSPB8 is a chaperone widely distributed in several (if not
all) human tissues, even if at different expression levels. In
addition, HSPB8 upregulation may protect in ALS and SBMA
(Carra et al., 2005, 2013; Crippa et al., 2010b; Rusmini
et al., 2013). Notably, HSPB8 mutations cause Charcot-Marie-
Tooth type 2L disease, hereditary distal motor neuropathy
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type II (dHMN-II) or distal myopathy (Fontaine et al., 2006;
Irobi et al., 2010; Ghaoui et al., 2016), diseases involving
motoneurons and/or muscle cells. These mutations impair the
chaperone HSPB8 activity (Kwok et al., 2011), suggesting it
has a crucial role in preserving motoneuron function and
viability. Here, we review experimental findings in support of this
hypothesis.
Interestingly, within the spinal cord, HSPB8 is specifically
found in motoneurons, and its expression declines with age
(Crippa et al., 2010b) suggesting that motoneurons might
become more vulnerable to misfolded protein toxicity during
aging. In cultured motoneurons, HSPB8 expression is greatly
induced by proteasome impairment (Figure 2; Crippa et al.,
2010a,b), a condition generally occurring in MNDs. In addition,
HSPB8mRNA expression is higher in autopsy specimens of ALS
patient spinal cord than in age-matched controls (Anagnostou
et al., 2010). We found a robust increase of HSPB8 protein levels
in anterior horn spinal cordmotoneurons surviving at end-stages
of disease in transgenic (tg) ALS SOD1-G93A mice compared
to wild-type mice (Crippa et al., 2010b), and this upregulation
correlates with the presence of diffuse and non-aggregated
mutant SOD (Crippa et al., 2010b).
FIGURE 2 | Regulation of protein quality control (PQC) system. When
misfolded proteins cannot be efficiently removed by degradative pathways,
misfolded proteins may accumulate and block ubiquitin proteasome system
(UPS) and autophagy. In this context, proteasome saturation by misfolded
proteins increases the transcription of HSPB8 (B8 in the figure) that, together
with its partners BAG3 and HSC70, routes misfolded proteins to autophagy. In
parallel, when dynein-mediated transport is blocked and autophagosomes
formation is inhibited, still unknown factors activate the de novo transcription
of BAG1, which binds to HSP70/CHIP and routes misfolded proteins to UPS.
HSPB8 is also highly expressed in muscle. Indeed, the
genome-wide tissue analysis of RNA and protein expression
(available at the Human Protein Atlas portal1) reports that
in human skeletal muscle HSPB8 mRNA is expressed at
high level, while the protein is expressed at medium levels
if compared to other human tissues (Uhlén et al., 2015). In
mice, HSPB8 expression in skeletal muscle dramatically increases
during disease progression in ALS (Carra et al., 2013; Crippa
et al., 2013a,b), and SBMA (Rusmini et al., 2015) mice. Since in
these two MNDs, both motoneurons and myoblasts are target
of misfolded protein toxicity, the increased HSPB8 expression
may contribute to enhance the aberrant proteins clearance from
muscle to improve cell survival. This hypothesis is supported
by a recent report showing that the protein ICP10PK, the
herpes simplex virus type 2 (HSV-2) homolog of HSPB8,
delays disease onset and slows down progression rate of
tg ALS SOD1-G93A mice (Aurelian et al., 2012). These
affects are associated to reduced damages at neuromuscular
junctions, and to increased motoneuronal survival (Aurelian
et al., 2012). We demonstrated that the overexpression
of HSP67Bc, the fly functional ortholog of HSPB8, exerts
protective effects in two Drosophila melanogaster models of
ALS. HSP67Bc overexpression prevented the mislocalization of
a neurotoxic mutant TDP-43 protein (Ritson et al., 2010), while
HSP67Bc downregulation correlated with increased TDP-43
and polyubiquitinated proteins accumulation, worsening the
eye phenotype, of mutant TDP-43 flies (Crippa et al.,
2016). HSP67Bc also rescued from pupae lethality flies
overexpressing the ALS-associated 35 kDa TDP-43 fragment
(TDP-35; Crippa et al., 2016). Thus, HSPB8 upregulation
protects against misfolded protein-mediated toxicity in ALS
models.
At cellular levels, the HSPB8 protective effects associate
to its capability to facilitate misfolded proteins autophagic
degradation. Indeed, HSPB8 could remove the blockage of
autophagic flux found in several NDs (Rusmini et al.,
2013, 2016; Giorgetti et al., 2015; Crippa et al., 2016).
The HSPB8 pro-degradative activity was demonstrated with
several different neuropathogenic proteins, like polyQ proteins
(ARpolyQ, huntingtin-polyQ, ataxin-3-polyQ), beta-amyloid,
alpha-synuclein, ALS proteins mutant SOD1 and TDP-43
fragments (Chávez Zobel et al., 2003; Wilhelmus et al., 2006;
Carra et al., 2008a,b; Crippa et al., 2010b, 2016; Bruinsma et al.,
2011; Seidel et al., 2012; Rusmini et al., 2013), and on five
different RAN translated DPRs from the C9Orf72 gene linked to
ALS and FTD (Cristofani et al., 2017b). In most cases, HSPB8
down-regulation resulted in increased accumulation of these
mutant proteins and DPRs, supporting its role in the misfoded
protein clearance (Crippa et al., 2010b, 2016; Rusmini et al., 2013;
Cristofani et al., 2017b).
Moreover, increasing genetic and experimental evidences
suggest that the RNA-protein inclusions accumulating in
ALS and similar NDs may arise from the conversion of
dynamic ribonucleoprotein complexes, stress granules (SGs),
into amyloid-like aggregates. In particular, misfolded proteins
1www.proteinatlas.org
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accumulating in SGs promote their conversion into aggregates.
Intriguingly, the PQC system response named ‘‘granulostasis’’,
surveys SG composition and maintains their dynamic behavior.
One of the key players of granulostasis is the HSPB8-BAG3-
HSP70 complex (Ganassi et al., 2016; Carra et al., 2017; Mateju
et al., 2017).
THE MOLECULAR MEDIATORS OF THE
HSPB8 PRO-AUTOPHAGIC ACTIVITY IN
MOTONEURONS
In line with the proposed pro-autophagic activity of HSPB8,
autophagy, but not proteasome inhibition blocks, the HSPB8
pro-degradative activity (Crippa et al., 2010b, 2016; Rusmini
et al., 2013). Mechanistically, HSPB8 facilitates the autophagic
clearance of misfolded protein by associating with BAG3
(in a 2:1 ratio) and HSP70 (Carra et al., 2008b). The
HSPB8-BAG3-HSP70 complex allows the cargoes delivery
(i.e. misfolded proteins) to autophagy for degradation
(Figure 1). BAG3 is essential in the complex, and its loss
leads to a fast HSPB8 degradation (Carra et al., 2008b). In
physiological conditions, the HSPB8-BAG3-HSP70 complex
is essential at muscle level for Z-disk maintenance, where
it is induced in response of acute physical exercise and
of repeated mechanical stimulation (Ulbricht et al., 2015).
These conditions generate a large excess of damaged proteins
(e.g., actin) by post-translational modifications (carbonylation,
nitrosylation), and the HSPB8-BAG3-HSP70 complex
recognizes these damaged proteins and, by interacting via
HSP70, with the E3-ubiquitin ligase CHIP/STUB1, forms
the CASA complex. Here, CHIP/STUB1 ubiquitinates the
target substrate allowing its SQSTM1/p62 recognition and
insertion into the autophagosomes for degradation (Arndt et al.,
2010). In skeletal muscle, the CASA complex directly interacts
with DNAJB6 (of the DNAJ/Hsp40 family; Sarparanta et al.,
2012), an HSP70 co-chaperone that suppresses aggregation
of several misfolded proteins involved in NDs (Hageman
et al., 2010). Indeed, DNAJB6 mutations cause Limb-girdle
muscular dystrophies (LGMDs) in which a less-effective
anti-aggregation activity of DNAJB6 has been found. In LGMDs
patient muscle biopsies, DNAJB6 and CASA complex proteins
aggregation and accumulation are observed, suggesting that the
pathogenesis is also mediated by CASA dysfunctions (Sandell
et al., 2016).
We demonstrated an important role of the CASA complex
in motoneurons under pathological conditions, since in
ALS cell models, this complex clears misfolded mutant
SOD1 accumulating into motoneurons (Crippa et al., 2010a,b).
While HSPB8 appears to be the limiting factor of this complex,
BAG3 mediates its formation acting as a scaffold which interacts
by its N-terminus with HSPB8 and by its C-terminus with
HSP70 (which binds CHIP/STUB1). BAG3 contains PXXP
motif, adjacent to the BAG domain, which binds dynein
(Merabova et al., 2015), and two binding sites for the 14-3-3
protein, which stabilizes the BAG3 and dynein interaction
(Mccollum et al., 2010; Behl, 2011, 2016; Gamerdinger et al.,
2011a,b; Xu et al., 2013; Jia et al., 2014; Merabova et al., 2015).
Dynein allows the efficient transport of the entire BAG3-multi-
heteromeric complex at the site of autophagosomes assembly
(Arndt et al., 2010; Crippa et al., 2010b; Merabova et al., 2015;
Figure 1).
Interestingly, when dynein mediated transport is genetically
(siRNAs) or pharmacologically (EHNA) blocked, the
HSP70-CHIP cannot bind HSPB8-BAG3 complex to dispose
misfolded proteins (ARpolyQ, mutant SOD1 and truncated
TDP-43) via autophagy (Cristofani et al., 2017a). Here, still
unknown factors activate the de novo transcription of another
NEF/BAG, the BAG1, which binds HSP70/CHIP re-routing
misfolded proteins to UPS (Behl, 2011, 2016; Gamerdinger
et al., 2011a; Cristofani et al., 2017a). Indeed, BAG1 exogenous
overexpression facilitates proteasomal removal of ARpolyQ.
When dynein transport is inhibited, the pro-degradative
BAG1 activity is blocked by proteasome inhibitors, but not by
autophagy blockers (Cristofani et al., 2017a; Figure 2).
The BAG3/BAG1 ratio is the key factor that determines the
fate of misfolded protein degradation via UPS or autophagy.
HSPB8, being a chaperone ‘‘holder’’, would bind to client
proteins keeping them in a competent state for further
processing by the BAG3-HSP70 complex. Increases in
HSPB8 levels restore a deficient autophagic flux and ensure
proper targeting of misfolded proteins to autophagy for clearance
(Figure 2).
HSPB8-BAG3 INDUCTION AS POSSIBLE
THERAPEUTIC APPROACH FOR MNDs
Since HSPB8 overexpression is sufficient to restore autophagy,
HSPB8 acts as a limiting factor for misfolded proteins autophagic
degradation. Thus, small molecules acting as HSPB8 inducers
may be of therapeutic interest in MNDs (Figure 2). Indeed,
estrogens are physiological HSPB8 inducers, and selective
estrogen receptor modulators (SERM) may differentially control
its expression (Sun et al., 2007; Piccolella et al., 2017). To
find FDA-approved drugs and natural compounds inducers of
HSPB8 expression, we performed a high throughput screening
(HTS) based on the human HSPB8 promoter controlling
luciferase expression. We identified colchicine and doxorubicin
as potent HSPB8 inducers and autophagy facilitators of removal
of insoluble TDP-43 species (Crippa et al., 2016). Colchicine and
derivatives might represent useful compounds to be tested in
ALS models. Besides colchicine, which may have side effects,
we found another HSPB8 inducer, the autophagic stimulator
trehalose (Rusmini et al., 2013), already tested with positive
results in several mice models of NDs (Tanaka et al., 2004; Davies
et al., 2006; Rodríguez-Navarro et al., 2010; Perucho et al., 2012;
Schaeffer and Goedert, 2012; Castillo et al., 2013; Du et al., 2013;
Sarkar et al., 2014; Zhang et al., 2014; He et al., 2016).
Recently, it was shown that trehalose was also able to
upregulate BAG3 expression (Lei et al., 2015). Whether
trehalose protective effect is partly mediated by HSPB8 and
BAG3 induction, in mice has still to be tested and represents
an attractive hypothesis for future studies. Other compounds
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able to induce BAG3 expression has not been tested in MNDs
models. Several evidences demonstrate that besides its role
in autophagy, both HSPB8 and BAG3 modulate intracellular
pathways involved in apoptosis or development altered in
several tumors, and pharmacological BAG3 upregulation is
obtained with proteasome inhibitors, TNF-related apoptosis-
inducing ligand, fludarabine, cytosine arabinoside and etoposide,
compounds used in chemotherapy, indicating BAG3 as a
mediator of therapy resistance (Romano et al., 2003; Chiappetta
et al., 2007; Rapino et al., 2014).
Thus, from preclinical studies, the pharmacological induction
of key molecules like HSPB8 or BAG3 represents a novel and
attractive target to treat MNDs. However, given the ability
of these proteins to modulate major biological processes, the
side-effects of their induction on other intracellular pathways
remain to be elucidated.
CONCLUSIONS
Data collected in recent years clearly demonstrated that an
increased PQC system activity protects against proteotoxic
stresses induced by MNDs associated with the accumulation
of misfolded proteins. Amongst the several PQC system
components, the chaperone HSPB8 has attracted great attention,
since it exerts a potent pro-degradative activity on misfolded
proteins facilitating their removal via autophagy and preventing
their intracellular accumulation. HSPB8 acts in a molecular
complex involved in the fine tuning of the equilibrium between
the UPS and autophagy. By this mechanism, HSPB8 also prevents
the delivery of excessive amounts of misfolded proteins to UPS
by routing them to autophagy. Based on these findings, the
pharmacological induction of HSPB8 in MND affected cells
should represent a promising therapeutic approach to counteract
disease onset and progression.
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